EN DE
Watch Solid Biosciences LLC for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Solid Biosciences LLC (SLDB) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Solid Biosciences LLC stock $4.91, price $6.48, that is 24.2% below the price, quality 35 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US83422E2046

SB Solid Biosciences LLC logo Thin data Nov 17, 2026

Solid Biosciences LLC

SLDB · US

Expensive (fair value 24% below the price) and weak company, but rising price: meets 1 of 3 rules.

Get notified free when this changes
Rising price (uptrend) 
Insiders sold $24,582 (6M) 
Fair value $4.91 · Overvalued 
Quality 35/100 
Weak Growth (revenue YoY −40.6 %/yr in USD) 
Negative free cash flow 
Trails peers (1/5) 
Narrow moat 5/100
Thin data 
Estimate
Watch Solid Biosciences LLC for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$48.00 $1.89 Fair Value $4.91 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.

How to read this chart

60‑month range $1.89 – $48.00 · fair‑value band $3.68 – $6.14 · the $6.48 price screens above the $4.91 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.

Follow Solid Biosciences LLC in your weekly email

Every Wednesday you see whether Solid Biosciences LLC is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy.

Show moreShow less

It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases.

In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid.

The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

Stock analysis

Solid Biosciences LLC (SLDB) currently trades at $6.48, while our estimate is $4.91, 24% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $3.68 (bear) to $6.14 (bull), the price of $6.48 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

Solid Biosciences LLC reported revenue of $0 in FY2025 versus $13.6M in FY2021. Reported net income was −$174M in FY2025.

Key figures

Market cap $931M Small · EPS (TTM) $−1.76 · Return on equity −65.5% · Return on assets (EBIT) −56.2% (5-year average) · Free cash flow −$157M · Net cash $106M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 5 out of 100 (medium confidence).

What moves the price

The share trades about 42% below its 52-week high and 49% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −24%, SLDB screens richer than that median.

Fair Value

Bear $3.68 Fair Value $4.91 Bull $6.14
Price $6.48 · Downside -24.2%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 35/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 25
Are margins and returns getting better?
Cashflow 26
Do the profits arrive as real cash?
Financial strength 72
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 41
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 61
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director sold shares worth $24,582 and none bought.

  • SaleGabriel BrooksChief Medical Officer4× since Feb 2, 2026: 45,325 shares, avg. $6.36$288,306Oct 19, 202610b5-1 plan
  • SaleKevin TanCFO & Treasurer4× since Jan 13, 2026: 52,728 shares, avg. $6.25$329,544Feb 18, 202610b5-1 plan
  • SaleDavid T HowtonChief Operating Officer4× since Dec 3, 2025: 69,066 shares, avg. $6.28$433,595Feb 18, 202610b5-1 plan
  • SalePaul HerzichChief Technology Officer4× since Dec 3, 2025: 43,472 shares, avg. $6.31$274,125Feb 18, 202610b5-1 plan
  • SaleIlan GanotDirector4× since Jan 5, 2026: 11,107 shares, avg. $6.20$68,846Feb 18, 2026
  • SaleJessie HanrahanChief Regulatory Officer4× since Dec 3, 2025: 47,500 shares, avg. $6.26$297,375Feb 18, 202610b5-1 plan
  • SaleAlexander CumboPresident and CEO, Director4× since Dec 3, 2025: 156,623 shares, avg. $6.28$983,958Feb 18, 202610b5-1 plan

Plus 3 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

SLDB screens overvalued: fair value 24% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Solid Biosciences LLC with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 847 stocks

Beats the industry median on 1/4 measures
Overall it trails its industry peers.
Valuation
Quality Score 35 · Below median
Fair Value upside −24.2% · Above median
Profitability
Return on assets −75.0% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 5.17× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)1 · sector 0
FUTURE (revenue growth)0 · sector 36
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 21

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs SLDB
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs SLDB
Samsung Biologics Co 207940 1,423,000 KRW 1,552,100 KRW +9% vs SLDB
argenx SE ARGX $950.95 $908.40 −4% vs SLDB
CSL Limited CSL A$199.55 A$186.49 −7% vs SLDB
Moderna, Inc MRNA $215.27 $135.64 −37% vs SLDB
BeOne Medicines AG 6160 HK$249.40 HK$152.92 −39% vs SLDB
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs SLDB
Celltrion, Inc 068270 214,500 KRW 74,945 KRW −65% vs SLDB
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs SLDB

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Solid Biosciences LLC: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Solid Biosciences LLC Fair Value". https://www.fairvalue-calculator.com/stock/SLDB

Frequently asked questions

Is Solid Biosciences LLC (SLDB) overvalued or undervalued?
As of Nov 17, 2026, our estimate of fair value is $4.91 versus a price of $6.48, about 24% lower (overvalued).
What is the fair value of SLDB?
Our estimate for Solid Biosciences LLC is $4.91 (as of Nov 17, 2026), built from audited fundamentals. The current price: $6.48.
What is the quality score of SLDB?
Solid Biosciences LLC has a Quality Score of 35/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Solid Biosciences LLC (SLDB)?
Our calculated price target is the estimate of $4.91 (as of Nov 17, 2026). Cautious scenario $3.68, optimistic scenario $6.14. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Solid Biosciences LLC stock forecast for 2026?
Our estimate puts fair value at $4.91, about 24% lower versus a price of $6.48 (overvalued). Cautious scenario $3.68, optimistic scenario $6.14. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Solid Biosciences LLC (SLDB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Solid Biosciences LLC it is $4.91 per share (as of Nov 17, 2026), against a price of $6.48.
Is Solid Biosciences LLC stock overvalued or undervalued in 2026?
As of Nov 17, 2026, SLDB trades above its calculated fair value: price $6.48, fair value $4.91, a gap of about −24% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SLDB?
No. The price is what the market pays today ($6.48); the fair value is what the company's own numbers justify ($4.91). For Solid Biosciences LLC the two are $1.57 per share apart. That gap is exactly why we show both numbers side by side.
How much is Solid Biosciences LLC worth?
The market values Solid Biosciences LLC at about $931M (market capitalisation, as of Nov 17, 2026). Per share that is $6.48; our models calculate a fair value of $4.91 per share.
What do the bullish and bearish scenarios say about SLDB?
Our models span a range for Solid Biosciences LLC: cautious scenario $3.68, base $4.91, optimistic $6.14 per share (as of Nov 17, 2026, price $6.48). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Solid Biosciences LLC (SLDB)?
Balance-sheet figures for Solid Biosciences LLC (as of Nov 17, 2026): return on equity −65.5%. They feed the Quality Score of 35/100, which measures business quality independently of the share price.
How far is SLDB from its 52-week high?
Solid Biosciences LLC trades at $6.48, about 42% below its 52-week high of $11.15 and 49% above the low of $4.34 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $4.91 is for.
Which stocks are comparable to Solid Biosciences LLC?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Solid Biosciences LLC stock attractive at the current price?
The data as of Nov 17, 2026: price $6.48, calculated fair value $4.91 (−24%), Quality Score 35/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Solid Biosciences LLC itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Solid Biosciences LLC (SLDB)?
The closing price on Nov 16, 2026 was $6.48. Our estimate is $4.91, about 24% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Solid Biosciences LLC right now?
The price sits above even our optimistic bull case ($6.14). The favourable scenario is already priced in. Weak quality (35/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Solid Biosciences LLC

How large is the market capitalisation of Solid Biosciences LLC (SLDB)?
The market capitalisation of Solid Biosciences LLC is $931M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Solid Biosciences LLC (SLDB)?
Earnings per share at Solid Biosciences LLC are $−1.76. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Solid Biosciences LLC (SLDB)?
The return on equity (ROE) of Solid Biosciences LLC is −65.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Solid Biosciences LLC (SLDB)?
On an EBIT basis the return on assets of Solid Biosciences LLC is −56.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Solid Biosciences LLC (SLDB) generate?
The free cash flow of Solid Biosciences LLC is −$157M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Solid Biosciences LLC (SLDB) hold?
Solid Biosciences LLC holds more cash than debt, $106M net (balance sheet 30 Sep 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Solid Biosciences LLC in the live analysis

One click puts Solid Biosciences LLC on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.